Therapy is designed to leave healthy cells alone, potentially limiting side effects
LONDON—AstraZeneca PLC has agreed to pay Japan’s Daiichi Sankyo Co. up to $6 billion to jointly develop and commercialize a cancer drug it says could help redefine the way the disease is treated, in the British company’s latest push into oncology.
The therapy, an antibody drug conjugate named DS-1062, targets a range of cancers—including lung and breast—that produce a protein known as TROP2. It is designed to deliver chemotherapy just to those cells, leaving healthy ones alone, potentially limiting side effects. ...
- - - - - - - - - -
AstraZeneca Strikes $6.9 Billion Cancer Deal With Japanese Drugmaker
Deal for part of the rights to Daiichi Sankyo’s antibody drug is part of Astra’s heavy investment in cancer research
AstraZeneca PLC has agreed to pay Japan’s Daiichi-Sankyo Co. up to $6.9 billion for shared rights to a new cancer drug, as the British drugmaker expands further in the oncology market.
The Japanese drugmaker, which will retain exclusive rights to the treatment in its home country, will get $1.35 billion upfront, with further payments dependent on the drug’s development and sales performance. In return, AstraZeneca said it will receive half the profit from future sales outside Japan. ...
